Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

The identification of molecular agents inhibiting specific functions in cancer cells
progression is considered as one of the most successful plans in cancer treatment. The …

The EGFR family is among the most investigated receptor protein-tyrosine kinase groups
owing to its general role in signal transduction and in oncogenesis. This family consists of …

Single-agent osimertinib is the standard of care for the first-line treatment of
advancedEGFR+ NSCLC and remained the only marketed third-generation EGFR tyrosine …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

Lung cancer causes the highest mortality compared to other cancers in the world according
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …